10-K: Tandem Diabetes Care Navigates Losses, Boosts Sales & Global Reach

Tandem Diabetes Care reported increased worldwide sales to over $1 billion in 2025, driven by higher pump shipments and international expansion, despite incurring significant net operating losses.

Summary

• Worldwide sales increased to $1.015 billion in 2025, up from $940.2 million in 2024.
• Net loss widened to $204.7 million in 2025, compared to a net loss of $96.0 million in 2024.
• Gross margin improved to 54% in 2025, up from 52% in 2024.
• Worldwide pump shipments increased to over 126,000 in 2025, from over 120,000 in 2024.
• U.S. sales increased to $706.9 million in 2025, primarily due to increased volumes and improved average selling prices.
• International sales grew to $307.8 million in 2025, driven by increased volumes, improved average selling prices, and favorable foreign currency exchange rates.
• Operating expenses rose to $733.3 million in 2025 from $588.7 million in 2024, largely due to $75.2 million in acquired in-process research and development (IPR&D) expenses and $20.0 million in litigation and settlement expense.
• The company had an accumulated deficit of $1.3 billion as of December 31, 2025.
• Cash and cash equivalents and short-term investments totaled $292.7 million as of December 31, 2025.
• Net cash used in operating activities was $9.7 million in 2025, a shift from $24.2 million provided in 2024.
• The company is implementing a multi-channel managed care strategy in the U.S., including a 'pay-as-you-go' pharmacy benefit model in 2026, which is expected to increase supply sales over time.
• Mobi with iOS control became commercially available in the U.S. in 2024 and expanded to Android users in December 2025.
• CE Mark approval for the Tandem Mobi insulin delivery system with Control-IQ+ technology was received in May 2025.
• Control-IQ+ technology was cleared for people living with type 2 diabetes ages 18 and older in March 2025.
• A patent dispute with F. Hoffman-La Roche AG and Roche Diabetes Care GmbH was settled in May 2025 for $36.0 million, with $13.3 million capitalized as an intangible asset.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While sales growth and gross margin improvement are positive, the significant increase in net loss and accumulated deficit, coupled with cash used in operations, indicates ongoing profitability challenges. Strategic initiatives and product pipeline are promising, but execution risks and competitive pressures remain high.

Positives

• Worldwide sales exceeded $1 billion in 2025, demonstrating continued revenue growth.
• Gross margin improved to 54% in 2025, up from 52% in 2024, indicating better cost management or pricing power.
• Increased worldwide pump shipments to over 126,000 in 2025, reflecting growing market adoption.
• Successful expansion of Mobi availability to Android users in the U.S. and CE Mark approval for Mobi with Control-IQ+ in Europe broadens market reach.
• Control-IQ+ technology cleared for Type 2 diabetes patients (ages 18+), expanding the addressable market.
• Resolution of a multi-year patent dispute with Roche through a cross-license agreement reduces legal uncertainty.
• Initiation of direct sales, training, and customer support activities in the UK, Austria, and Switzerland in 2026 signals strategic international expansion.
• Strong focus on employee culture, organizational development, and competitive total rewards supports talent retention and innovation.

Negatives

• Net loss significantly widened to $204.7 million in 2025 from $96.0 million in 2024, indicating a deterioration in profitability.
• Accumulated deficit reached $1.3 billion as of December 31, 2025, highlighting historical and ongoing losses.
• Net cash used in operating activities was $9.7 million in 2025, a negative shift from cash provided in 2024.
• Operating expenses increased substantially, driven by $75.2 million in acquired IPR&D and $20.0 million in litigation and settlement costs.
• Non-recurring facility impairment costs of $6.7 million and restructuring costs of $4.2 million impacted SG&A expenses in 2025.
• A $14.2 million loss from an equity method investment contributed to the overall net loss in 2025.
• The transition to a 'pay-as-you-go' pharmacy benefit model in 2026 may initially cause a decrease in sales and gross profit when pumps are shipped.
• The company faces significant competition from major medical device companies and new technological developments that could render products obsolete.
• Product recalls (e.g., March 2024 iOS t:connect app recall, July 2025 t:slim X2 medical device correction) pose reputational and financial risks.
• The personal relationship between the CEO and CFO is noted as potentially creating a perceived risk to internal controls.

Risks

• Incurred significant operating losses since inception and cannot assure sustained profitability.
• Reliance on sales of insulin pump products; negative impacts on these sales could adversely affect business.
• Multi-channel managed care strategy (pharmacy channel) may fail to achieve intended outcome, impacting growth and financial condition.
• Ability to maintain and grow sales depends on retaining a high percentage of the customer base.
• Failure to secure or retain adequate coverage or reimbursement by third-party payors could adversely affect business.
• Competing products, therapeutic techniques, or technological developments may render products obsolete or less desirable.
• Sales and marketing efforts depend on independent distributors who may market competing products.
• Dependence on clinical investigators and sites for trials; failure to complete could prevent regulatory approvals.
• Concerns regarding safety or efficacy of products could limit sales and cause negative effects.
• Dependence on a limited number of third-party suppliers for components and products; loss or inability to supply could harm business.
• Commercializing internationally involves various risks (regulatory, intellectual property, economic, political, currency fluctuations).
• Failure to obtain required regulatory authorization in foreign jurisdictions will prevent marketing.
• Servicing Convertible Senior Notes due 2029 requires significant cash flow, which may not be sufficient.
• Need to raise additional funds in the future; inability to do so could prevent strategic objectives.
• Operating results may fluctuate significantly from quarter to quarter.
• Uncertainty in global economic and political conditions could adversely affect product demand and financial results.
• Public health threats, epidemics, or pandemics could have a material adverse effect on operations.
• Sales and profits may fluctuate or decline due to changes in foreign currency exchange rates.
• Subject to stringent and evolving data privacy and security laws; failure to comply could lead to regulatory actions, litigation, fines, and reputational harm.
• Information technology systems or data compromise could lead to adverse consequences.
• Ability to comprehensively protect intellectual property is uncertain.
• Patent litigation in the medical device industry is common and costly.
• May be subject to damages from claims of wrongful use or disclosure of trade secrets.
• Products and operations are subject to extensive governmental regulation; failure to comply could cause business to suffer.
• New products or modifications may require new regulatory clearances/approvals, or require cessation of marketing/recall.
• A recall or suspension of products, or discovery of serious safety issues, could have a significant negative impact.
• Failure to comply with federal and state fraud and abuse laws could have a material adverse impact.
• Legislative or regulatory healthcare reforms may result in downward pressure on prices and decreased reimbursement.
• Advertising and promotion with comparative claims could expose to heightened regulatory scrutiny and litigation.
• Direct-to-consumer marketing and social media initiatives may subject to increased regulatory scrutiny.
• ESG regulations, initiatives, and requirements could expose to various risks and higher costs.
• Climate change or extreme weather conditions may impact business.
• Price of common stock may continue to fluctuate significantly.
• Dependence on senior management and key employees; inability to retain or recruit could harm business.
• Anti-takeover provisions in organizational documents and Delaware law may delay or prevent a change of control.
• Failure to successfully manage acquisitions or investments could have a material adverse effect.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Uncertainties in interpretation and application of tax laws could materially affect tax obligations.
• Failure to maintain an effective system of internal control over financial reporting could harm business.

Future Outlook

The company expects continued business growth, including expansion of customer service, international commercial sales, manufacturing, warehousing, and R&D activities, which will lead to increased expenses. A transition to a 'pay-as-you-go' pharmacy benefit model in the U.S. in 2026 is anticipated, which may initially decrease pump sales and gross profit but is expected to be offset by increased supply sales and overall higher revenue per customer over four years. The company plans to continue increasing sales through the pharmacy benefit with improved scalability and expanded coverage in 2026, and will continue direct sales transition in additional international markets across 2026. The product pipeline includes enhancing t:slim X2 and Mobi platforms, adding a tubeless, extended-wear infusion site option for Mobi, and a next-generation Mobi patch pump leveraging Sigi Patch Pump technology. Development efforts also include extended-wear infusion set technology, dual glucose-ketone sensor integration, and algorithm advancement towards fully closed-loop technology. Operating results are expected to fluctuate periodically due to new product launches, regulatory clearances, seasonality, and the competitive environment. The company anticipates less seasonal impact on business in future periods related to insurance deductibles due to pharmacy benefit expansion and expects to rely primarily on product sales to fund material cash requirements in both the short and long term.

Management Comments

• Our strategy is to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights.
• We consider our addressable market to be people living with type 1 diabetes and in 2025, we began expanding our addressable market to include people living with type 2 diabetes who require intensive insulin therapy.
• We believe this offering [Tandem Device Updater] is a competitive advantage, allowing us to bring our customers clinical and lifestyle enhancements within their warranty cycle without having to purchase a new pump.
• Our goal is to redefine global leadership in insulin delivery solutions through commercial excellence, patient-first reimbursement choices, and a differentiated device portfolio.
• We believe that our cash and cash equivalents, short-term investments, and future cash flows from operations will be sufficient to fund our ongoing core business activities for at least the next twelve months.
• We are committed to creating and maintaining a safe, diverse, and inclusive community for all employees while we serve our customers and fulfill our mission to improve the lives of people with diabetes.
• We believe that bringing together different perspectives and experiences is fundamental to innovation and continuing to raise the bar in the field of diabetes technology.

Industry Context

StockSavvy.ai notes that Tandem Diabetes Care operates in a highly competitive and rapidly evolving medical device industry, particularly in diabetes management. The company's expansion into the Type 2 diabetes market and its multi-channel reimbursement strategy, including the 'pay-as-you-go' pharmacy model, are strategic moves to capture a larger market share and adapt to changing healthcare financing landscapes. The emphasis on advanced AID algorithms like Control-IQ+ and integration with multiple CGM sensors (Dexcom, Abbott FreeStyle Libre) positions Tandem to compete with major players like Insulet and Medtronic, who also offer advanced insulin delivery systems. The industry is also facing challenges from the increasing adoption of GLP-1 class drugs for diabetes and obesity, which could negatively impact the insulin therapy market. Regulatory changes, such as the EU MDR and HTA Regulation, and U.S. competitive bidding processes, continue to shape market access and reimbursement, requiring companies to adapt their compliance and commercial strategies.

Comparison to Industry Standards

• Tandem's Control-IQ+ technology, with published pivotal studies in the New England Journal of Medicine, demonstrates a commitment to clinical evidence, comparable to leading medical device companies in the diabetes space.
• The company's gross margin of 54% in 2025, while an improvement, should be benchmarked against competitors like Insulet (Omnipod) and Medtronic (MiniMed) to assess its competitive pricing and cost efficiency within the durable and disposable pump segments.
• The transition to a 'pay-as-you-go' pharmacy model aligns with broader industry trends to improve patient access and affordability, a strategy also pursued by some competitors to reduce upfront costs for consumers.
• The global insulin pump market remains highly underpenetrated (approximately 40% Type 1, 5% Type 2 in U.S.; 20% internationally), indicating significant growth potential that Tandem is actively pursuing through international expansion and Type 2 market entry, similar to other global diabetes device manufacturers.
• The company's reliance on third-party suppliers for critical components (e.g., Unomedical A/S for infusion sets) is a common industry practice but also a shared risk, requiring robust supply chain management comparable to industry best practices.

Corporate Governance

Legal Proceedings

• On May 21, 2025, the company entered into a Settlement, Mutual Release and Cross-License Agreement with F. Hoffman-La Roche AG and Roche Diabetes Care GmbH, resolving all actual or potential patent disputes as of that date.
• As of December 31, 2025, the company believes it is not currently a party to any legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount or range of loss was reasonably estimable.

Stakeholder Impact

• Shareholders face dilution risk from the conversion of 2029 Notes and potential negative impacts on stock price due to financial fluctuations, competitive pressures, or adverse results. However, they may benefit from strategic growth and product innovation.
• Employees benefit from the company's commitment to a safe, diverse, and inclusive community, comprehensive training programs, and competitive total rewards including equity awards. They may be impacted by labor shortages or changes in work models.
• Customers are offered improved access and flexibility through the multi-channel reimbursement strategy and benefit from new product features and integrations (Mobi, Control-IQ+, CGM integrations). They face potential risks from product recalls or safety concerns.
• Suppliers face risks due to the company's dependence on a limited number of third-party suppliers, which could lead to disruptions. They are also exposed to macroeconomic factors and trade policies.
• Creditors, particularly holders of the 2029 Notes, rely on the company's future cash flow to service its debt, with a risk of default if cash flow is insufficient.

Next Steps

• Continue increasing sales through the pharmacy benefit with improved scalability of operations and expanded coverage in 2026.
• Transition to a 'pay-as-you-go' reimbursement structure in the pharmacy channel in 2026.
• Continue direct sales transition in additional international markets across 2026.
• Enhance features and capabilities of t:slim X2 and Mobi insulin pump platforms.
• Add a tubeless, extended-wear infusion site option for Mobi users.
• Develop a next-generation Mobi patch pump incorporating Sigi Patch Pump technology.
• Develop extended-wear infusion set technology.
• Integrate dual glucose-ketone sensors.
• Advance algorithms in pursuit of offering fully closed-loop technology.
• Expand Mobi integration offerings to include Abbott FreeStyle Libre 3 Plus.
• Monitor and comply with evolving ESG regulations and reporting standards.
• Monitor and evaluate the potential impacts of Pillar Two tax rules.

Key Dates

Recommendation

Tandem Diabetes Care shows promising strategic initiatives with new product launches and market expansion, alongside improved gross margins. However, the significant increase in net losses and cash used in operations, coupled with substantial accumulated deficit and various operational and regulatory risks, suggests a cautious approach. The transition to a new reimbursement model introduces near-term uncertainty. Investors should hold to observe the successful execution of these strategies and a clear path to sustained profitability before considering further investment.

Keywords

Diabetes Care, Insulin Pump, Medical Device, Control-IQ+, Tandem Mobi, t:slim X2, Healthcare Technology, CGM, Automated Insulin Delivery, Financial Results, SEC Filing, 10-K, Corporate Governance, Risk Factors, Nasdaq, TNDM, Biotechnology, Health Tech, Regulatory Compliance, Financial Reporting